This article presents two cases of advanced lung adenocarcinoma successfully treated with furmonertinib, aiming to provide clinical insights for this rare patient population and explore the therapeutic potential of EGFR-TKIs in compound mutations. The gene discussed is EGFR; the disease is lung adenocarcinoma.